Please login to the form below

Not currently logged in
Email:
Password:
Rare diseases

Companies developing rare disease treatments face several unique challenges when it comes to regulatory and reimbursement submissions.

The most pressing of these include the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs) as well as the challenges associated with collecting appropriate evidence in rare diseases. Alongside this is determining the needs for HTA and payer bodies to ensure a positive value assessment and reimbursement.

As well as these challenges, there are fundamental issues for clinical trial design that are magnified in rare diseases such as determining appropriate sample sizes and comparators and generating evidence to support selected endpoints.

On 22 March this PMLiVE webinar, in association with Adelphi Values, will use real-world examples to highlight the importance of evidence such as appropriate endpoints, including COAs, and comparators in rare diseases to support regulatory and reimbursement submissions. 

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics